TY - CHAP M1 - Book, Section TI - Therapy of Heart Failure A1 - Eschenhagen, Thomas A2 - Brunton, Laurence L. A2 - Hilal-Dandan, Randa A2 - Knollmann, Björn C. Y1 - 2017 N1 - T2 - Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13e AB - Heart failure is responsible for more than half a million deaths annually in the U.S. Its prevalence is increasing worldwide, likely due to improved survival of those who have had an acute myocardial infarction and an aging population. Median survival rates after the first hospitalization associated with heart failure are worse than those of most cancers, but have improved over the past 30 years (1.3 to 2.3 years in men and 1.3 to 1.7 years in women) (Jhund et al., 2009). This positive trend was associated with a 2- to 3-fold higher prescription rate of ACEIs and ARBs, β receptor antagonists (β blockers), and MRAs, suggesting that improved drug therapy has contributed to enhanced survival of heart failure. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/10/05 UR - accessanesthesiology.mhmedical.com/content.aspx?aid=1162538503 ER -